BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new inte

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third qu

Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for

KING OF PRUSSIA, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the

Vertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property

Corient Private Wealth LP purchased a new position in Vertex, Inc. (NASDAQ: VERX) in the second quar

CRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editin

VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targ

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday reported data from its Phase 2b AMPLIFI

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a

Vertex Pharmaceuticals NASDAQ: VRTX is continuing to broaden its business beyond cystic fibrosis, wi

Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commer

Vertex Pharmaceuticals NASDAQ: VRTX outlined a broadening commercial and clinical strategy at the Ca

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with m

Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow

Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript

Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas.

Vertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic

KING OF PRUSSIA, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to

Gainers Corvex (NASDAQ:MOVE) stock moved upwards by 44.6% to $15.56 during Tuesday's regular se

DA Davidson analyst Lucky Schreiner maintains Vertex (NASDAQ:VERX) with a Neutral and lowers the

Vertex Inc (NASDAQ:VERX) reported strong Q2 earnings, exceeding analyst estimates. Sales for Q3 also

Stephens & Co. analyst Brett Huff maintains Vertex (NASDAQ:VERX) with a Overweight and lowers

Baird analyst Rob Oliver maintains Vertex (NASDAQ:VERX) with a Outperform and lowers the price ta

Vertex (NASDAQ:VERX) narrows FY2026 sales outlook from $823.500 million-$831.500 million to $825.000

Vertex (NASDAQ:VERX) reported quarterly earnings of $0.20 per share which beat the analyst consensus

Morgan Stanley analyst Chris Quintero downgrades Vertex (NASDAQ:VERX) from Overweight to Equal-We

TD Cowen analyst Jared Levine initiates coverage on Vertex (NASDAQ:VERX) with a Buy rating and an

Goldman Sachs sees a familiar pattern returning in 2026: prior-year laggards often beat the S&P

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earni

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earn

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn

Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear

  Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to repor

  On Tuesday, 951 companies hit new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.